1. Home
  2. OSPN vs ALT Comparison

OSPN vs ALT Comparison

Compare OSPN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneSpan Inc.

OSPN

OneSpan Inc.

HOLD

Current Price

$11.15

Market Cap

449.1M

Sector

Technology

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$5.13

Market Cap

415.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSPN
ALT
Founded
1991
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
449.1M
415.3M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
OSPN
ALT
Price
$11.15
$5.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$17.00
$16.00
AVG Volume (30 Days)
476.8K
5.6M
Earning Date
02-26-2026
02-26-2026
Dividend Yield
4.29%
N/A
EPS Growth
99.92
N/A
EPS
1.49
N/A
Revenue
$241,436,000.00
$20,000.00
Revenue This Year
$0.69
N/A
Revenue Next Year
$1.96
N/A
P/E Ratio
$7.52
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.00
$2.90
52 Week High
$20.37
$7.73

Technical Indicators

Market Signals
Indicator
OSPN
ALT
Relative Strength Index (RSI) 33.97 55.36
Support Level $11.26 $5.19
Resistance Level $12.21 $5.75
Average True Range (ATR) 0.52 0.57
MACD -0.08 0.06
Stochastic Oscillator 38.16 49.59

Price Performance

Historical Comparison
OSPN
ALT

About OSPN OneSpan Inc.

OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: